Search Results - "Ramez, Eskander N"

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy by Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Boichard, Amelie, Nikanjam, Mina, Weihe, Elizabeth, Kuo, Dennis J., Eskander, Ramez N., Goodman, Aaron, Galanina, Natalie, Fanta, Paul T., Schwab, Richard B., Shatsky, Rebecca, Plaxe, Steven C., Sharabi, Andrew, Stites, Edward, Adashek, Jacob J., Okamura, Ryosuke, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle

“…Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is…”
Get full text

Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer by Eskander, Ramez N., MD, Tewari, Krishnansu S., MD

“…Abstract Purpose In 2014, the US Food and Drug Administration approved the first targeted agent, bevacizumab, in the treatment of advanced stage, persistent,…”
Get full text

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients by Charo, Lindsey M., Eskander, Ramez N., Okamura, Ryosuke, Patel, Sandip P., Nikanjam, Mina, Lanman, Richard B., Piccioni, David E., Kato, Shumei, McHale, Michael T., Kurzrock, Razelle

“…In gynecologic cancer patients, therapy matched to ctDNA alterations (N = 33 patients) was independently associated with improved overall survival (hazard…”
Get full text

PARP Inhibitors in Epithelial Ovarian Cancer by Taylor, Kristin N, Eskander, Ramez N

“…Ovarian cancer remains the most common lethal gynecologic malignancy. The therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced…”
Get more information

Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test by Hinestrosa, Juan Pablo, Kurzrock, Razelle, Lewis, Jean M., Schork, Nicholas J., Schroeder, Gregor, Kamat, Ashish M., Lowy, Andrew M., Eskander, Ramez N., Perrera, Orlando, Searson, David, Rastegar, Kiarash, Hughes, Jake R., Ortiz, Victor, Clark, Iryna, Balcer, Heath I., Arakelyan, Larry, Turner, Robert, Billings, Paul R., Adler, Mark J., Lippman, Scott M., Krishnan, Rajaram

“…Background Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before…”
Get full text

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials by Eskander, Ramez N., Powell, Matthew A.

“…The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and…”
Get full text

Overcoming the challenges of drug development in platinum-resistant ovarian cancer by Eskander, Ramez N., Moore, Kathleen N., Monk, Bradley J., Herzog, Thomas J., Annunziata, Christina M., O’Malley, David M., Coleman, Robert L.

“…The definition of “platinum-resistant ovarian cancer” has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard…”
Get full text

Fertility preserving options in patients with gynecologic malignancies by Eskander, Ramez N., MD, Randall, Leslie M., MD, Berman, Michael L., MD, Tewari, Krishnansu S., MD, Disaia, Philip J., MD, Bristow, Robert E., MD

“…A proportion of reproductive age women are affected by gynecologic malignancies. This patient population is faced with difficult decisions, related to their…”
Get full text

Targeting angiogenesis in advanced cervical cancer by Eskander, Ramez N., Tewari, Krishnansu S.

“…Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with…”
Get full text

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer by Eskander, Ramez N, Tewari, Krishnansu S

“…The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent…”
Get full text

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy by Louie, Bryan H., Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Okamura, Ryosuke, Eskander, Ramez N., Botta, Gregory, Patel, Hitendra, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle

“…Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of…”
Get full text

Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies by Eskander, Ramez N, Tewari, Krishnansu S

“…Given the prevalence of phosphatase & tensin homolog mutations in histologic specimens harvested from patients with endometrial cancer, significant interest in…”
Get more information

Survey of trends in authorship assignment in gynecologic oncology: Keeping score and playing fair by Chambers, Laura M., Watson, Catherine H., Yao, Meng, Levinson, Kimberly, Alvarez, Ronald D., Eskander, Ramez N., Buechel, Megan, Michener, Chad M., Jernigan, Amelia

“…•30.6% of responding gynecologic oncologists reported assignment of authorship that did not meet ICMJE criteria.•The majority reported that ICMJE criteria were…”
Get full text

Revisiting immunotherapy in endometrial cancer by Eskander, Ramez N

Get full text

De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening by Hahn, Erin E., Munoz-Plaza, Corrine, Altman, Danielle E., Hsu, Chunyi, Cannizzaro, Nancy T., Ngo-Metzger, Quyen, Wride, Patricia, Gould, Michael K., Mittman, Brian S., Hodeib, Melissa, Tewari, Krishnansu S., Ajamian, Lena H., Eskander, Ramez N., Tewari, Devansu, Chao, Chun R.

“…Abstract Background New cervical cancer screening guidelines recommend primary human papillomavirus (HPV) testing for women age 30–65 years. Healthcare…”
Get full text

Clinical trials, adaptability and the COVID-19 pandemic by Eskander, Ramez N., Pothuri, Bhavana, Randall, Leslie, O'Malley, David, Slomovitz, Brian, Moore, Kathleen, Coleman, Robert, Herzog, Thomas, Monk, Bradley J., Copeland, Larry

“…•The COVID-19 pandemic has required adaptability in the workplace.•Women health care professionals are disproportionately affected by the burdens resulting…”
Get full text

Top advances of the year: Uterine cancer by Erickson, Britt K., Slomovitz, Brian, Powell, Matthew, Eskander, Ramez N.

“…Endometrial cancer continues to be the only gynecologic malignancy with a rising incidence and mortality, with both regional and global implications…”
Get full text

Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency by Eskander, Ramez N.

“…Understanding the prognostic implications of mismatch repair deficiency in endometrial cancer may inform future therapy. Opportunity remains to expand on the…”
Get full text

Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer by Longoria, Teresa C, Eskander, Ramez N

“…Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due…”
Get more information

Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line by Eskander, Ramez N., Randall, Leslie M., Sakai, Toshinori, Guo, Yi, Hoang, Bang, Zi, Xiaolin

“…Aim:  To examine the effects of flavokawain B (FKB), a novel kava chalcone, on the growth of uterine leiomyosarcoma (LMS) cells and investigated its utility in…”
Get full text